Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

Thumbnail

Obama’s FY15 budget allocates $77B for HHS

President Obama has unveiled his $3.9 trillion fiscal year 2015 budget proposal, which allocates $77.1 billion to support the Department of Health & Human Services and $1.8 billion for health IT incentive payments.

SGR Repeal Faces a New Threat: Politics

House Republicans may tie passing a permanent repeal of the sustainable growth rate (SGR) formula to delaying the Affordable Care Act (ACA) individual mandate on buying health insurance.

Doctors Seek CMS Help on ACA Insurer Rule that Puts Practices at Risk

Current requirements for when insurers must tell physician practices that a patient’s Affordable Care Act (ACA) insurance exchange purchased health plan is in danger of being cancelled could leave doctors unreimbursed for their services warned more than 80 state and national organizations in a letter to CMS.

CMS/ONC seeking public comment on pediatric quality measures

The Centers for Medicare & Medicaid Services and the Office of the National Coordinator for Health IT have released additional draft quality measures under their Children’s Measures project.

Thumbnail

Senators Introduce Bill to Fix “Two Midnight Rule”

U.S. Senators Robert Menendez (D-N.J.) and Deb Fisher (R-Neb.) have introduced legislation that would require CMS to change its new guidelines around when a Medicare patient hospital stay is judged to be an inpatient stay.

Thumbnail

Congress questions CMS, OIG on MU incentive fraud

On the heels of an indictment that accused a former Texas healthcare executive of collecting $800,000 in EHR incentive payments under false pretenses, lawmakers from the House Committee on Energy and Commerce are looking for answers from the Centers for Medicare & Medicaid Services (CMS) and the Office of Inspector General (OIG) on why fraud is happening within the program.

Catalyst for Payment Reform Executive Director Breaks Down Pay-for-Performance

In a continuing Health Affairs series, Catalyst for Payment Reform Executive Director Suzanne Delbanco digs into the evidence for Pay-for-Performance (often called P4P) as a payment system that may potentially reduce overall health care costs.According to Delbanco, pay-for-performance may indeed be useful in shifting providers toward new payment systems because it only has an upside. You get a bonus if you improve certain quality measures and you earn the same if you don't.However, she warns that the lack of financial risk in P4P may limit its usefulness. Research also has not shown that it can lower costs, a key purpose of new payment systems. Finally, it may encourage physicians to focus on a narrow band of measurable quality measures to the detriment of the overall quality of the care the patient receives.Delbanco theorizes that the true value of P4P may be as a stepping stone to shared-risk arrangements with payors.

NYT: “New Law’s Demands on Doctors Have Many Seeking a Network”

The many regulatory, reimbursement and policy changes related to the Patient Protection and Affordable Care Act are undoubtedly changing the business climate for physicians. In a feature with video, the New York Times contrasts the practices of two Kentucky primary care doctors — Sven Jonsson, M.D., and Tracy Ragland, M.D. — to illustrate the economic pressure pushing many sole practitioners into employment by large health care networks.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.